In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight
"An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device"
its usually short-lived and manageable
Complete a short health questionnaire so our clinical team understands your goals
Understanding how many peptides can be combined safely is essential for designing multi-target protocols
Sterile water evaporates faster and does not contain the preservative (benzyl alcohol) that keeps your solution safe for multiple uses